Nrf2 as a Master Regulator in Liver Disease Prevention and Therapy

描述（由申请人提供）：目前用于治疗肝病的治疗干预非常有限;治疗靶点的鉴定是开发治疗肝病新药的先决条件。氧化应激和炎症在肝脏疾病的发病机制中起关键作用。核因子2相关因子2（Nrf 2）是一种在肝细胞和免疫细胞中表达的转录因子，是抗氧化和抗炎反应的关键因子。在静止的肝细胞中，Nrf 2被kelch样ECH相关蛋白1（Keap 1）隔离在细胞溶质中;在Keap 1敲低小鼠中，Nrf 2的核转位增加，导致Nrf 2靶基因的激活。Nrf 2在细胞保护中的重要性是公认的。然而，Nrf 2在肝脏病理生理学中的作用最近才受到关注。我们的长期目标是确定一个新的药物靶点，并开发一种治疗/预防肝病的策略。该R 01拨款提案的目的是深入研究Nrf 2在保护肝脏病理生理学方面的作用，并了解其潜在的分子机制。基于我们强有力的初步数据，我们的中心假设是Nrf 2通过其在肝脏中多种细胞类型中的生物转化/处置、抗氧化、组织修复和抗炎中的多方面作用而成为肝脏保护的主要调节剂。目的1将使用ChIP测序鉴定Nrf 2调节的直接靶点，并确定Keap 1敲低小鼠中Nrf 2依赖性mRNA诱导。目的2将测试Nrf 2激活保护肝脏疾病的化学，饮食和遗传模型的假设。我们将使用3种具有不同Nrf 2活性的小鼠遗传模型，即Nrf 2缺失、野生型和Nrf 2增强小鼠，在13种不同模型中测试肝病易感性。目标3将与治疗，发现和开发办公室合作，通过高通量筛选开发新的和特异性的Nrf 2激活剂先导候选物。我们提出的研究是新颖的，因为它利用3种具有不同Nrf 2活性的小鼠品系来研究Nrf 2缺乏和Nrf 2激活对通过不同毒性机制诱导的肝脏疾病的相反影响。该提案利用创新技术，包括ChIP测序，多重mRNA分析和核易位高通量筛选，以测试3个目标。我们提出的研究是重要的，因为我们的实验结果将提供有关Nrf 2缺陷和Nrf 2激活在肝脏病理生理学及其潜在分子机制中的重要性的坚实证据，为开发Nrf 2激活剂作为治疗/预防各种肝脏疾病的新药奠定科学基础，如化学诱导的肝损伤，炎症性肝病，脂肪性肝炎和肝纤维化/肝硬化。公共卫生相关性：肝病是一种常见疾病，但与大多数其他疾病相比，肝衰竭的药物很少。我们假设Nrf 2是一种必需的转录因子，是一种可用于预防和治疗各种肝脏疾病的药物靶点。这项研究将确定这种药物靶点是否对广泛的肝病动物模型有效。

DESCRIPTION (provided by applicant): Current therapeutic interventions for treating liver diseases are very limited; identification of a therapeutic target is a prerequisite for developing new drugs to treat liver diseases. Oxidative stress and inflammation play key roles in the pathogenesis of liver diseases. Nuclear factor 2-related factor 2 (Nrf2), a transcription factor expressed in both hepatocytes and immune cells, is a key factor in anti-oxidative and anti-inflammatory responses. In quiescent hepatocytes, Nrf2 is sequestered in cytosol by kelch-like ECH-associated protein 1 (Keap1); in Keap1-knockdown mice, nuclear translocation of Nrf2 increases, resulting in activation of Nrf2 target genes. The importance of Nrf2 in cytoprotection is recognized. Nevertheless, the role of Nrf2 in liver pathophysiology has just recently gained attention. Our long-term goal is to identify a novel drug target and develop a therapeutic/preventive strategy for liver diseases. The objective of this R01 grant proposal is to investigate in-depth the role of Nrf2 in protecting against liver pathophysiology and understand its underlying molecular mechanisms. Based upon our strong preliminary data, our central hypothesis is that Nrf2 is a master regulator of liver protection through its multifaceted roles in biotransformation/disposition, antioxidation, tissue- repair, and anti-inflammation in multiple cell types in liver. Aim 1 will identify direct targets of Nrf2 regulation using ChIP-Sequencing and determine Nrf2-dependent mRNA induction in the Keap1-knockdown mouse. Aim 2 will test the hypothesis that Nrf2 activation protects against chemical, dietary, and genetic models of liver disease. We will use 3 genetic models of mice with differential Nrf2 activity, namely Nrf2-null, wild-type, and Nrf2-enhanced mice, to test liver disease susceptibility in 13 different models. Aim 3 will develop novel and specific Nrf2 activator lead candidates by high throughput screening in collaboration with the Office of Therapeutics, Discovery, and Development. Our proposed study is novel, because it utilizes 3 mouse lines with different Nrf2 activities to investigate the opposing effects of Nrf2 deficiency and Nrf2 activation on liver diseases induced via diverse mechanisms of toxicity. This proposal utilizes innovative techniques including ChIP-sequencing, multiplex mRNA analysis, and nuclear translocation high throughput screening in testing the 3 aims. Our proposed study is significant, because results from our experiments will provide solid evidence regarding the importance of Nrf2 deficiency and Nrf2 activation in liver pathophysiology and its underlying molecular mechanisms, setting the scientific foundation for developing Nrf2 activators as novel drugs to treat/prevent various liver diseases, such as chemical-induced liver injury, inflammatory liver diseases, steatohepatitis, and liver fibrosis/cirrhosis. PUBLIC HEALTH RELEVANCE: Liver disease is a common ailment, however in contrast to most other diseases, there are very few drugs for liver failure. We hypothesize that Nrf2, an essential transcription factor, is a drug target that can be used to prevent and treat a wide-range of liver ailments. This study will determine whether this drug target will be effective against a wide-spectrum of animal models of liver disease.